- Fragments of Bird Flu Virus Found in 1 in 5 Milk Samples
- Clients Got HIV Through ‘Vampire Facial’ Microneedling Treatments
- Take the Stairs & Step Up to Longer Life
- ‘Drug Take Back Day’ is Saturday: Check for Leftover Opioids in Your Home
- Loneliness Can Shorten Lives of Cancer Survivors
- A Stolen Dog Feels Like Losing a Child, Study Finds
- Healthier Hearts in Middle Age Help Black Women’s Brains Stay Strong
- Better Scans Spot Hidden Inflammation in MS Patients
- Which Patients and Surgeries Are ‘High Risk’ for Seniors?
- Vancomycin May Be Losing Strength Against Common Deadly Infection
Vistogard Approved for Chemotherapy Overdose
Vistogard (uridine triacetate) has been approved by the U.S. Food and Drug Administration to treat an overdose of chemotherapy drugs commonly used to treat cancers of the breast and gastrointestinal tract.
The drugs are fluorouracil and capecitabine. An overdose of either drug, while rare, can be life-threatening, the FDA said Friday in a news release.
Treatment with Vistogard should begin as soon as possible after the overdose, even if any symptoms of overdose aren’t present, the agency warned. The user’s doctor should then determine when a return to chemotherapy is appropriate.
Vistogard is designed to minimize cell damage caused by chemotherapy. The drug was evaluated in clinical studies involving 135 children and adults who either had taken an overdose of chemotherapy or had developed a life-threatening toxic reaction within 96 hours of being given chemotherapy. Of clinical trial participants given Vistogard, 89 percent to 97 percent were still alive after 30 days, the agency said.
Vistogard is not recommended for non-emergency adverse reactions associated with chemotherapy, as the new drug could weaken the effects of chemotherapy, the FDA said. Vistogard’s most common side effects included diarrhea, vomiting and nausea.
Vistogard is marketed by Gaithersburg, Md.-based Wellstat Therapeutics.
More information
The FDA has more about this approval.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.